HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Pharmacogenomics (London)

• Publication date

  2008-11-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2217/14622416.9.11.1617PMID 19018717
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Carbamazepine and phenytoin induced Stevens‐Johnson syndrome is associated with HLA‐B*1502 allele in Thai population

  2008cited by this paper
• Abacavir Hypersensitivity Reaction: an Update

  2008cited by this paper
• HLA-B*5701 screening for hypersensitivity to abacavir.

  2008cited by this paper
• A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

  2008cited by this paper
• HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese

  2008cited by this paper
• High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

  2008cited by this paper
• Human leukocyte antigen genotypes in carbamazepine‐induced severe cutaneous adverse drug response in Japanese patients

  2008cited by this paper
• Toxic epidermal necrolysis.

  2007cited by this paper
• Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han Chinese

  2007cited by this paper
• Stevens-Johnson Syndrome, Drug-Induced Hypersensitivity Syndrome and Toxic Epidermal Necrolysis Caused by Allopurinol in Patients with a Common HLA Allele: What Causes the Diversity?

  2007cited by this paper
• Medical Genetics: A Marker for Stevens-Johnson SyndromeChung W-H, Hung S-I, Hong H-S, et al (Chang Gung Mem Hosp, Taipei, Taiwan; Inst of Biomedical Sciences, Taipei, Taiwan) Nature 428:486, 2004§

  2006cited by this paper
• HLA-B locus in Caucasian patients with carbamazepine hypersensitivity.

  2006cited by this paper
• Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

  2006cited by this paper
• Toxic epidermal necrolysis: current evidence, practical management and future directions

  2005cited by this paper
• HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

  2005cited by this paper
• Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

  2004cited by this paper
• Co-amoxiclav jaundice: clinical and histological features and HLA class II association

  2000cited by this paper
• Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis Are Severity Variants of the Same Disease which Differs from Erythema Multiforme

  1997cited by this paper
• Report of the Japanese Central Bone Marrow Data Center.

  1996cited by this paper
• Severe adverse cutaneous reactions to drugs.

  1995cited by this paper
• Severe adverse cutaneous reactions to drugs.

  1994cited by this paper
• Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.

  1993cited by this paper
• [Stevens-Johnson syndrome].

  1962cited by this paper
• Stevens-Johnson syndrome.

  1947cited by this paper

• Atypical Intra‐Oral Lesions in a Young Epileptic Patient: A Case Report

  2025cites this paper
• A review of the immunogenetics of Stevens-Johnson syndrome and toxic epidermal necrolysis

  2025cites this paper
• Molecular docking to investigate HLA-associated idiosyncratic drug reactions

  2025cites this paper
• An Updated Economic Evaluation of HLA‐B*58:01 Genotype Testing in Gouty Patients for Preventing Severe Allopurinol Hypersensitivity in Thailand

  2025cites this paper
• A comprehensive update on the human leukocyte antigen and idiosyncratic adverse drug reactions

  2025cites this paper
• Effect of Computerized Physician Order Entry Reminders on HLA-B*15:02 Screening Rates: A Retrospective Study in a Taiwanese Hospital

  2025influential citation
• HLA-B*58:01 genotyping prevalence and the association with allopurinol-induced severe cutaneous adverse reactions: a living systematic review and meta-analysis

  2025cites this paper
• High-Resolution HLA-B Allele and Haplotype Frequencies in the Qatari Population: Implications for Pre-Emptive Pharmacogenetic Screening of Drug Hypersensitivity

  2025cites this paper
• Prevalence of Human Leukocyte Antigen (HLA)‐B*58:01 and Allopurinol‐Induced Adverse Reactions in Filipino Patients in Hawai'i: Implications for Genotyping

  2025cites this paper
• Risk factors for drug hypersensitivity reactions in children

  2024cites this paper
• Implementing HLA-B*58:01 testing prior to allopurinol initiation in Malaysian primary care setting: A qualitative study from doctors’ and patients’ perspective

  2024cites this paper
• Prevalence of HLA-B*58:01 allele among Malay, Chinese and Indian ethnic patients with gout attending primary care clinics in Malaysia

  2024cites this paper
• Toxic epidermal necrolysis caused by phenobarbital: a case report and literature review

  2024cites this paper
• Update on HLA-B*15:02 allele associated with adverse drug reactions.

  2024cites this paper
• Pharmacogenomics predictors of aromatic antiepileptic drugs-induced SCARs in the Iraqi patients

  2024cites this paper
• Human leukocyte antigen class II (DRB1 and DQB1) alleles frequencies in patients with bullous pemphigoid, Stevens Johnson syndrome and toxic epidermal necrolysis in Russian population

  2024cites this paper
• The role of biotransformation and chemical structure of drugs in the diagnosis of drug allergies

  2024cites this paper
• Stevens–Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management

  2024cites this paper
• Phenomic landscape and pharmacogenomic implications for HLA region in a Taiwan Han Chinese population

  2024cites this paper
• Hyperuricemia – consequences of not initiating therapy. Benefits and drawbacks of treatment

  2024cites this paper
• Clinical Profiles of Japanese Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Collected by a Nationwide System from 2006 to 2023.

  2024cites this paper
• Differential effects of HLA-B*15:11 and HLA-A*31:01 on carbamazepine-induced cutaneous adverse reactions.

  2023cites this paper
• Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients.

  2023cites this paper
• Overlapping Stevens-Johnson Syndrome and DRESS Syndrome Caused by Phenobarbital: A Vietnamese Case Report

  2023cites this paper
• Fatal toxic epidermal necrolysis associated with sinomenine in a patient with primary membranous nephropathy

  2023cites this paper
• Genotypic and Phenotypic Characteristics of Co-Trimoxazole-Induced Cutaneous Adverse Reactions

  2023cites this paper
• Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.

  2023cites this paper
• Cost-effectiveness of HLA-B*58:01 testing to prevent Stevens-Johnson syndrome/toxic epidermal necrolysis in Vietnam.

  2023cites this paper
• Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review

  2023cites this paper
• Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options

  2023cites this paper
• Validation of a genotyping technique for a surrogate marker of HLA-B∗58:01 for allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in the Japanese population.

  2023cites this paper
• Severe ocular complications of SJS/TEN and associations among pre-onset, acute, and chronic factors: a report from the international ophthalmology collaborative group

  2023cites this paper
• The allopurinol metabolite, oxypurinol, drives oligoclonal expansions of drug‐reactive T cells in resolved hypersensitivity cases and drug‐naïve healthy donors

  2023cites this paper
• New insights into the diagnosis and management of Stevens–Johnson syndrome and toxic epidermal necrolysis

  2023cites this paper
• Genetic markers of drug hypersensitivity in pediatrics: current state and promise

  2022cites this paper
• Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population

  2022influential citation
• Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis

  2022cites this paper
• Distribution of HLA-B Alleles and Haplotypes in Qatari: Recommendation for Establishing Pharmacogenomic Markers Screening for Drug Hypersensitivity

  2022cites this paper
• Drug-Induced Hypersensitivity Syndrome (DIHS)/ Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

  2022cites this paper
• Susceptibility Genes and HLA for Cold Medicine-Related SJS/TEN with SOC

  2022cites this paper
• Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics.

  2022cites this paper
• The Immunogenetics of Cutaneous Drug Reactions.

  2022cites this paper
• Evolution of HLA-B Pharmacogenomics and the Importance of PGx Data Integration in Health Care System: A 10 Years Retrospective Study in Thailand

  2022cites this paper
• Incidence of allopurinol‐induced severe cutaneous adverse drug reaction in Malaysia

  2022cites this paper
• Pharmacogenomics of Drug Hypersensitivity: Technology and Translation.

  2022cites this paper
• The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study

  2022cites this paper
• Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.

  2022cites this paper
• An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice

  2022cites this paper
• Genetic Determinants in HLA and Cytochrome P450 Genes in the Risk of Aromatic Antiepileptic-Induced Severe Cutaneous Adverse Reactions

  2021cites this paper
• Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus: two cases report

  2021cites this paper
• Heater Integrated Lab-on-a-Chip Device for Rapid HLA Alleles Amplification towards Prevention of Drug Hypersensitivity

  2021cites this paper
• Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art

  2021cites this paper
• Genetics of Severe Cutaneous Adverse Reactions

  2021cites this paper
• Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions

  2021cites this paper
• Stevens Johnson syndrome: A review of a vision and life-threatening mucocutaneous disease including histopathology with updates on pathogenesis and genetic risk factors

  2021cites this paper
• Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  2021cites this paper
• Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles

  2021cites this paper
• HLA-A*24:07 as a potential biomarker for carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Filipino patients.

  2021cites this paper
• Genetic Variants Associated With Drug-Induced Hypersensitivity Reactions: towards Precision Medicine?

  2021cites this paper
• A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine

  2021cites this paper
• Predominant HLA Alleles and Haplotypes in Mild Adverse Drug Reactions Caused by Allopurinol in Vietnamese Patients with Gout

  2021cites this paper
• Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine

  2021cites this paper
• Findings by an International Collaboration on SJS/TEN With Severe Ocular Complications

  2021cites this paper
• Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis

  2021cites this paper
• Human leucocyte antigen association of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications in Han Chinese

  2021cites this paper
• Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis

  2020cites this paper
• Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions

  2020cites this paper
• HLA-B*58:01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia

  2020cites this paper
• Real‐world evidence of population differences in allopurinol‐related severe cutaneous adverse reactions in East Asians: A population‐based cohort study

  2020cites this paper
• Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper

  2020cites this paper
• How Mechanism Knowledge Can Help to Management of Drug Hypersensitivity

  2020cites this paper
• Genetic Diversity of HLA Class I and Class II Alleles in Thai Populations: Contribution to Genotype-Guided Therapeutics

  2020influential citation
• Development of a HLA-B*58: 01 Allele Screening System for Allopurinol-Induced Severe Cutaneous Adverse Reactions Detection

  2020cites this paper
• A case of idiosyncratic liver injury after oxaliplatin‐induced thrombocytopenia

  2020cites this paper
• Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications

  2020cites this paper
• Pharmacogenomics

  2020cites this paper
• Association of carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients

  2020cites this paper
• Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis

  2019cites this paper
• Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity

  2019cites this paper
• Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real‐world patients: A nationwide study

  2019cites this paper
• Development of a rapid and reliable single-tube multiplex real-time PCR method for HLA-A*24:02 genotyping.

  2019cites this paper
• HLA-B*5801 et réactions cutanées à l’allopurinol dans la population Kinh d’Ho Chi Minh Ville (Vietnam)

  2019cites this paper
• Heart disease and the risk of allopurinol-associated severe cutaneous adverse reactions: a general population–based cohort study

  2019cites this paper
• Stevens‐Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study

  2019cites this paper
• Diagnostic Utility of Human Leukocyte Antigen B*15:02 Screening in Severe Carbamazepine Hypersensitivity Syndrome

  2019influential citation
• An update on HLA alleles as pharmacogenetic markers for antiepileptic drug-induced cutaneous adverse reaction

  2019cites this paper
• The Presence of HLA-B75, DR13 Homozygosity, or DR14 Additionally Increases the Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in HLA-B*58:01 Carriers.

  2019cites this paper
• Clinical features, outcomes and treatment in children with drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis

  2019cites this paper
• Cost‐effectiveness of screening for HLA‐B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States

  2019cites this paper
• Pharmacogenomics as a Tool for Management of Drug Hypersensitivity Reactions

  2019cites this paper
• Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

  2019cites this paper
• An Update On the Immunological, Metabolic and Genetic Mechanisms in Drug Hypersensitivity Reactions.

  2019cites this paper
• Genetic testing for prevention of severe drug-induced skin rash.

  2019cites this paper
• Early biomarkers for severe drug hypersensitivity reactions.

  2019cites this paper
• Allopurinol suppresses expression of the regulatory T‐cell migration factors TARC/CCL17 and MDC/CCL22 in HaCaT keratinocytes via restriction of nuclear factor‐κB activation

  2018cites this paper
• Case Report Treatment of a Severe Pediatric Lyell Syndrome with Amniotic Membrane : Case Report and Histological Findings

  2018cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

  2018cites this paper
• Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention

  2018cites this paper
• Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

  2018influential citation
• 7 Severe Cutaneous Adverse Reactions

  2018cites this paper